331 related articles for article (PubMed ID: 16571601)
1. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
[TBL] [Abstract][Full Text] [Related]
2. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
3. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
[TBL] [Abstract][Full Text] [Related]
5. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
Fisher TS; Lo Surdo P; Pandit S; Mattu M; Santoro JC; Wisniewski D; Cummings RT; Calzetta A; Cubbon RM; Fischer PA; Tarachandani A; De Francesco R; Wright SD; Sparrow CP; Carfi A; Sitlani A
J Biol Chem; 2007 Jul; 282(28):20502-12. PubMed ID: 17493938
[TBL] [Abstract][Full Text] [Related]
6. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
7. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
[TBL] [Abstract][Full Text] [Related]
8. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
9. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
Berge KE; Ose L; Leren TP
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1094-100. PubMed ID: 16424354
[TBL] [Abstract][Full Text] [Related]
10. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
Benjannet S; Rhainds D; Essalmani R; Mayne J; Wickham L; Jin W; Asselin MC; Hamelin J; Varret M; Allard D; Trillard M; Abifadel M; Tebon A; Attie AD; Rader DJ; Boileau C; Brissette L; Chrétien M; Prat A; Seidah NG
J Biol Chem; 2004 Nov; 279(47):48865-75. PubMed ID: 15358785
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G
Atherosclerosis; 2008 Feb; 196(2):659-66. PubMed ID: 17765244
[TBL] [Abstract][Full Text] [Related]
12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
15. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
16. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
[TBL] [Abstract][Full Text] [Related]
17. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.
Fasano T; Sun XM; Patel DD; Soutar AK
Atherosclerosis; 2009 Mar; 203(1):166-71. PubMed ID: 19081568
[TBL] [Abstract][Full Text] [Related]
18. Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage.
Cameron J; Holla ØL; Laerdahl JK; Kulseth MA; Berge KE; Leren TP
Atherosclerosis; 2009 Mar; 203(1):161-5. PubMed ID: 19022446
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.
Strøm TB; Tveten K; Leren TP
Biochem J; 2014 Jan; 457(1):99-105. PubMed ID: 24144304
[TBL] [Abstract][Full Text] [Related]
20. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
